Financial Data and Key Metrics Changes - In Q2 2024, net revenue was $3.25 million, down 8% compared to Q2 2023, primarily due to low contributions from emergency response revenue [9][10] - Gross margin remained strong at 59%, flat year-over-year, but decreased from 62% in Q1 2024 due to increased shipping expenses and reserves for slow-moving products [10] - Net loss improved by 33% to $289,000 in Q2 2024 from a loss of $433,000 in Q2 2023, attributed to reduced SG&A expenses [10][11] - For the first half of 2024, net loss decreased 38% to $458,000 from $739,000 in the prior year [11] Business Line Data and Key Metrics Changes - Non-emergency response business increased by 8% year-over-year in Q2 2024, while emergency response business saw a 92% decline [6][9] - Excluding emergency response revenue, sales increased by 10% in the first half of 2024 [10] Market Data and Key Metrics Changes - The company achieved the highest number of active customer sites ever, with a 15% increase over the previous year, totaling 1,384 active accounts by the end of Q2 2024 [6][19] Company Strategy and Development Direction - The company is focusing on long-term growth initiatives, including the expansion of digital tools like the filter tracking app to enhance customer engagement [7][8] - Nephros is strategically positioning itself to capitalize on growth opportunities in sectors beyond hospitals, such as dental practices and endoscopy processing [8] Management's Comments on Operating Environment and Future Outlook - Management noted a decline in emergency response business due to reduced stringency in waterborne risk response, but anticipates potential recovery with upcoming regulatory changes [7][15] - The company remains committed to innovation and customer engagement while focusing on profitability and return on investment [12] Other Important Information - The balance sheet remains strong with a cash balance of approximately $3.1 million as of June 30, 2024, despite a decrease from $4.3 million at the end of 2023 [11] Q&A Session Summary Question: Can you elaborate on the reduced stringency for waterborne risk response? - Management identified that the Ohio Department of Health reduced testing due to system overload, which may lead to a return to higher emergency responses with upcoming regulatory changes [14][15] Question: Update on the filter tracker rollout? - The rollout faced initial issues but recent updates have improved functionality. Management believes the tracker will help increase reorder rates for filters [17][18] Question: Total number of active accounts at the end of Q2? - The total number of active accounts as of the end of Q2 2024 was 1,384 [19]

Market Overview - The company develops and sells high-performance water filtration products primarily for medical and commercial markets, focusing on ultrafilters that capture contaminants as small as 0.005 microns [63]. - As of 2023, there are approximately 6,129 hospitals in the U.S. with around 920,000 beds, and over 34 million patients were admitted, highlighting a significant market for infection control solutions [70]. - The dialysis market includes approximately 7,100 clinics servicing around 500,000 patients annually, with the company's ultrafilters being standard in many portable reverse osmosis systems [75]. - The company anticipates that water safety management programs currently in medical facilities will migrate to commercial markets, increasing demand for its filtration solutions [78]. - The company believes future revenue from the commercial market could surpass its infection control revenue as demand for water testing and microbiological filtration grows [80]. Product Offerings - The company has FDA 510(k) clearance for multiple medical device products, including the DSU-H and SSU-H ultrafilters, which have product lives of up to 6 months and 3 months, respectively, in hospital settings [71]. - The NanoGuard product line offers 0.005-micron ultrafiltration technology, designed to filter organic and inorganic particles, and is compatible with various plumbing configurations [80]. - The EndoPur ultrafilter, used in large RO systems for dialysis clinics, has a product life of up to 12 months and is designed for easy installation without plumbing modifications [76]. Financial Performance - Total net revenues decreased by $0.3 million, or 8%, for the three months ended June 30, 2024, primarily due to decreased revenue from emergency response orders [85]. - Consolidated gross margin remained stable at approximately 59% for the three months ended June 30, 2024, compared to the same period in 2023 [86]. - Selling, general and administrative expenses decreased by $298,000, or 13%, primarily due to a reduction in bonus accrual and sales commission expenses [86]. - Research and development expenses increased by approximately $33,000, or 15%, due to an increase in headcount [86]. - Net loss for the three months ended June 30, 2024, was $289,000, a decrease of 33% compared to a net loss of $433,000 in the same period in 2023 [84]. - Total net revenues decreased by $0.5 million, or 6%, for the six months ended June 30, 2024, primarily driven by decreased revenue from emergency response orders [89]. - Consolidated gross margin increased to approximately 61% for the six months ended June 30, 2024, compared to approximately 58% for the same period in 2023 [90]. - Interest income increased to approximately $46,000 for the six months ended June 30, 2024, compared to approximately $25,000 for the same period in 2023 [92]. - Net cash used in operating activities was $1.2 million for the six months ended June 30, 2024, compared to net cash provided by operating activities of approximately $0.5 million for the same period in 2023 [97]. - As of June 30, 2024, the company had an accumulated deficit of $144.9 million and may incur additional operating losses until profitability is achieved [94]. Management and Controls - The company maintains a system of disclosure controls and procedures designed to provide reasonable assurance that required information is communicated to management in a timely manner [105]. - Management, including the CEO and CFO, concluded that the disclosure controls and procedures were effective as of the end of the reporting period [106]. - There were no changes in internal control over financial reporting during the most recent fiscal quarter that materially affected the internal control [107]. Strategic Initiatives - The company entered into a new supply agreement in January 2023 with a partner to be the exclusive distributor for water filtration systems to the food, beverage, and hospitality industries, potentially increasing commercial market revenue [77]. - The company has a strategic focus on expanding its market presence through value-added resellers (VARs), facilitating growth in filter sales outside the medical industry [66].

SOUTH ORANGE, NJ, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its second-quarter financial results on Thursday, August 8, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows: Domestic access: 1 (844) 808-7106 International access: 1 (412) 317-5285 Upon joining, please ...

SOUTH ORANGE, NJ, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its second-quarter financial results on Thursday, August 8, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows: Domestic access: 1 (844) 808-7106 International access: 1 (412) 317-5285 Upon joining, please ...

Nephros, Inc. (NASDAQ:NEPH) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Kirin Smith - Investor Relations Robert Banks - Chief Executive Officer Judy Krandel - Chief Financial Officer Conference Call Participants Thomas McGovern - Maxim Group Nick Farwell - Arbor Group Ralph Weil - R. Weil Investment Management Operator Good afternoon, and welcome to the Nephros, Inc. First Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode. [Operator ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _______ to _______ Commission File Number: 001-32288 NEPHROS, INC. (Exact name of registrant as specified in its charter) DELAWARE 13-3971809 (State or other ...

Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Financial Results for Quarter Ended March 31, 2024 First-Quarter Net Revenue of $3.5 Million; Technology advancements and microplastics capabilities on the horizon SOUTH ORANGE, NJ, May 09, 2024 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the first quarter ended ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32288 NEPHROS, INC. (Exact name of registrant specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 13-39 ...

Nephros, Inc. (NASDAQ:NEPH) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Kirin Smith - PCG Advisory Robert Banks - CEO Judy Krandel - CFO Conference Call Participants Nick Sherwood - Maxim Group Operator Good day, and welcome to the Nephros Inc. Fourth Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation there will be an opportunity to ask questions. [Operator Instructions] Please no ...

Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call:201 343 5202 nephros.com Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.3 Million SOUTH ORANGE, NJ, March 7, 2024 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended Decemb ...